Perrigo | PRGO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Abbott USD 6.65B 787M 2026-06
Bayer EUR 6.33B 1.84B 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Corcept Therapeutics USD 252.09M 90.07M 2026-06
Dr.Reddys Laboratories INR 41.78B 4.02B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
J&J USD 18.55B 1.31B 2026-06
Merck USD 12.09B 1.24B 2026-03
Nestle CHF 19.99B 1.44B 2026-06
Pacira USD 133.91M 7.27M 2026-06
Perrigo USD 313.9M 11.6M 2026-06
Pfizer USD -248M 11.29B 2026-06
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 136.19M 10.11M 2026-06
Reckitt Benckiser GBP 4.25B 2.08B 2024-12
Sanofi EUR 8.71B 602M 2026-06
Supernus Pharmaceuticals USD 160.06M 30.7M 2026-06
Teva Pharmaceutical Industries USD 2.15B 45M 2026-06
Xeris Pharmaceuticals USD 72.55M 404K 2026-03
Zoetis USD 1.76B 140M 2026-06